CGABL vs TECH · rev $5.43B vs P/E 65, rev $1.22B
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 (CGABL) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 (CGABL) common stock listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported CGABL revenue for 2024-12-31 was $5.43B. Net income was $1.09B. Revenue was up 83.1% from 2023-12-31 to 2024-12-31. CGABL currently screens at market cap $16.14B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
CGABL currently screens at market cap $16.14B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the CGABL and TECH stock pages for the full models.
Not investment advice.